Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04928807 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Mar 20, 2026 to Mar 20, 2028 Secondary endpoints revised (5)v5 Show 1 more changeShow less
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date changed from estimate of Jul 20, 2022 to Mar 1, 2023 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 230 to confirmed 231 · Completion date: Jul 20, 2025 to Mar 20, 2026 · 1 morev4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 230 to confirmed 231
    • Completion date: Jul 20, 2025 to Mar 20, 2026
    • Site details revised
  3. Study title expanded, about 1 wordv3 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Aug 31, 2023 to Jul 20, 2022 · Completion date: Sep 30, 2026 to Jul 20, 2025 · Start date changed from estimate of Jul 9, 2021 to Jul 20, 2021 · 1 morev2 Show 4 more changesShow less
    • Primary completion date: Aug 31, 2023 to Jul 20, 2022
    • Completion date: Sep 30, 2026 to Jul 20, 2025
    • Start date changed from estimate of Jul 9, 2021 to Jul 20, 2021
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a multicenter, open-label, randomized controlled clinical study, and the purpose of the study is to compare the pathological complete response rate (PCR) of patients with locally advanced rectal cancer treated with short-term radiotherapy, sequential Camrelizumab and CAPOX (group A) to long-term concurrent chemoradiotherapy, sequential CAPOX (group B) in patients with LARC. A total of 230 patients were included in this study.
Trial Details
NCT Number NCT04928807
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Rectal Cancer
Enrollment 231 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov